Inactive Instrument

OvaScience Inc Stock price Nasdaq

Equities

US69014Q1013

Biotechnology & Medical Research

Dynamic Chart
Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement CI
Millendo Therapeutics, Inc. Joins Nicholas Maestas as Vice President, Strategy and Finance and It's Principal Financial Officer CI
Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from NASDAQ Composite Index CI
Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million. CI
Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals MT
Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Transcript : Millendo Therapeutics, Inc., Tempest Therapeutics Inc. - M&A Call
Millendo Therapeutics : Tempest, Millendo Agree to Merge, Combined Company to List on NASDAQ MT
Millendo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Tempest Therapeutics Inc. entered into a definitive agreement and plan of merger to acquire Millendo Therapeutics, Inc. in a reverse merger transaction. CI
Millendo Therapeutics, Inc. Announces Executive Changes CI
Millendo Therapeutics, Inc. Plans to Reduce Its Workforce with Majority of Reduction in Personnel Expects to Complete by April 15, 2021 CI
MILLENDO THERAPEUTICS : Ladenburg Thalmann Downgrades Millendo Therapeutics to Neutral from Buy MT
MILLENDO THERAPEUTICS : SVB Leerink Downgrades Millendo Therapeutics to Market Perform From Outperform; Price Target is $2 MT
More news
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
More about the company
  1. Stock
  2. Equities
  3. Stock Millendo Therapeutics
  4. Stock OvaScience Inc - Nasdaq